FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1337-1339 September 27, 2007 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Zou, Y. PubMed Citation

Renal transplantation as the treatment of choice for end-stage renal failure is associated with excellent short-term results. The 1-year patient-survival rate is 96%, and the 1-year allograft-survival rate is more than 90%. Although the 5-year patient-survival rate after renal transplantation remains at about 90%, there is a steady attrition of allografts because of long-term rejection, which limits the 5-year allograft-survival rate to about 80%.¹

In the more than half century since the first clinical renal transplantations in the early 1950s, the procedure has become standard practice. There has been steady progress in allograft survival since the development of proper HLA . . . [Full Text of this Article]

Source Information

From the Institute for Clinical Transfusion Medicine and Immunogenetics, and the Institute for Transfusion Medicine, University Hospital — both in Ulm, Germany.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.